These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A comparison of acrivastine versus terfenadine and placebo in the treatment of chronic idiopathic urticaria.
    Author: van Joost T, Blog FB, Westerhof W, Jansen FC, Starink TM, den Boer MS, Kuneman JJ, Harvey SG, Gibson JR.
    Journal: J Int Med Res; 1989; 17 Suppl 2():14B-17B. PubMed ID: 2569995.
    Abstract:
    Patients (n = 56) with a diagnosis of chronic idiopathic urticaria were assessed in a fully randomized, double-blind, crossover study to investigate the efficacy of acrivastine at two doses (8 and 4 mg) versus 60 mg terfenadine and placebo administered three times daily. All three active preparations were found to be effective, and significantly better than placebo, in controlling the signs and symptoms of urticaria. No significant differences were found between the active preparations, although in some cases efficacy trends favoured 8 mg acrivastine and terfenadine over 4 mg acrivastine. No significant differences were noted between the active treatments and placebo with regard to reports of drowsiness.
    [Abstract] [Full Text] [Related] [New Search]